biopharma dive - Robuta Search

https://www.biopharmadive.com/news/ionis-metagenomi-crispr-gene-editing-deal/636338/ Ionis teams with Metagenomi and dives into gene editing | BioPharma Dive The RNA drug developer is paying the richly funded startup $80 million in a wide-ranging alliance that marks its first foray into DNA editing medicines. gene editing biopharma dive ionis teams metagenomi https://www.biopharmadive.com/news/allogene-restructuring-strategy-car-t-lymphoma-trial/703643/ Allogene to shift strategy in bid to reposition CAR-T | BioPharma Dive The company plans to restructure and will start a new late-stage study testing whether its “off-the-shelf” therapy can boost cure rates when used early on. biopharma dive allogene shift strategy bid https://www.biopharmadive.com/news/fda-drug-shortage-coronavirus-first-impact/573190/ FDA reports first drug shortage due to coronavirus impact | BioPharma Dive Supplies of the drug, which the FDA did not identify, ran short as a result of issues at a site that produces the active ingredient. Other options are... due to coronavirus impact biopharma dive fda reports https://www.biopharmadive.com/news/als-drug-research-progress-genetic-clinical-trials/611274/ On the hunt for new ALS drugs, researchers see progress, and a long road ahead | BioPharma Dive The fatal nerve disease has few treatments. But despite continued setbacks, drug developers are hopeful that genetic technologies and a better understanding of... on the hunt long road ahead biopharma dive new als https://www.biopharmadive.com/news/biohaven-vyglxia-spinocerebellar-ataxia-fda-europe/759167/ Biohaven’s rare disease drug is ‘ready to ship on Day 1’ following FDA approval | BioPharma Dive CEO Vlad Coric said the company has a patient hub, payer managers and a small sales force set up to ensure a successful launch of Vyglxia, a brain medicine... rare disease fda approval biopharma dive drug ship https://www.biopharmadive.com/news/epicrispr-fshd-series-b-financing-epigenetic-editing/743366/ Epicrispr banks $68M to test epigenetic editing on rare muscle disease | BioPharma Dive The startup is using CRISPR tools to stop errant expression of a gene linked to facioscapulohumeral muscular dystrophy, a disorder on the radars of several... epigenetic editing muscle disease biopharma dive banks test https://www.biopharmadive.com/news/elicio-angion-reverse-merger-ipo-biotech-startups/640486/ With reverse merger, Elicio becomes latest biotech to bypass an IPO | BioPharma Dive Elicio’s combination with Angion Biomedica comes months after it abandoned a new stock offering, and is the latest example of how the IPO slowdown has shifted... reverse merger biopharma dive elicio becomes latest https://www.biopharmadive.com/news/biomarin-roctavian-limit-sales-us-germany-italy-hemophilia/723402/ BioMarin pares Roctavian spending as it narrows sales focus | BioPharma Dive The company plans to limit sales of the hemophilia gene therapy to the U.S., Italy and Germany, while ending most clinical development work. biopharma dive biomarin pares roctavian spending https://www.biopharmadive.com/news/provention-diabetes-rejection-fda/602866/ FDA knocks back diabetes prevention drug, crushing its maker's shares | BioPharma Dive Provention Bio said it expects to collect data that could address the FDA's concerns before the end of September. In the meantime, though, the company's shares... knocks back biopharma dive fda diabetes prevention https://www.biopharmadive.com/news/weird-ingredients-biopharma/428918/ Witch's brew? What drugs contain leech and lizard parts | BioPharma Dive From Gila monster spit to sloth fur, biopharma has increasingly incorporated strange additions into its drugs. biopharma dive witch brew drugs contain https://www.biopharmadive.com/news/kailera-triple-G-obesity-drug-phase-1-data-hengrui/821191/ Kailera’s three-pronged obesity shot shows promise in early trial | BioPharma Dive As Lilly completes the pivotal program for its “triple-G” drug, Phase 1 data from Kailera partner Hengrui suggest their offering might spur greater weight loss. in early biopharma dive three pronged obesity https://www.biopharmadive.com/news/ethyreal-bio-graves-thyroid-eye-disease-tshr/822477/ Ethyreal starts up with $101M and takes aim at a pair of immune diseases | BioPharma Dive The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related... starts up takes aim pair of biopharma dive immune https://www.biopharmadive.com/news/lilly-morphic-novartis-morphosys-pelabresib-parker-cancer-agenus/721835/ Lilly alone in bidding for Morphic; Novartis won’t yet file MorphoSys drug | BioPharma Dive Federal filings showed no companies other than Lilly made an offer to buy Morphic, while Novartis executives said they’re still waiting for more data on... biopharma dive lilly alone bidding morphic https://www.biopharmadive.com/news/sanofi-scribe-gene-editing-nk-cell-therapy-cancer/632718/ Sanofi partners with Scribe to gain gene editing tools for cell therapy work | BioPharma Dive The California biotech will receive $25 million upfront from Sanofi, which plans to use Scribe’s platform to edit natural killer cells for cancer treatment. gene editing cell therapy biopharma dive sanofi partners https://www.biopharmadive.com/news/abbvie-fda-rinvoq-approval-jak-inhibitor/561112/ Price, safety will test blockbuster billing for AbbVie's new arthritis drug | BioPharma Dive Rinvoq adds another oral option to rheumatologists' tool kits, but at a list price of $59,000 per year. biopharma dive price safety test blockbuster https://www.biopharmadive.com/news/merck-epstein-barr-vaccine-opko-modex/644449/ Merck pays $50 million for early-stage Epstein-Barr vaccine | BioPharma Dive Opko’s acquisition of ModeX paid off with a Merck deal that could earn the vaccine and immunotherapy developer hundreds of millions of dollars. early stage epstein barr biopharma dive merck pays https://www.biopharmadive.com/news/lundbeck-alzheimers-failure-idalopirdine/435747/ Lundbeck brings latest Alzheimer's failure | BioPharma Dive The Danish drugmaker reported two late-stage failures that put an end to its 5-HT6 antagonist in yet another setback for the space. biopharma dive lundbeck brings latest alzheimer https://www.biopharmadive.com/news/lilly-siteone-acquisition-pain-drug-non-opioid-deal/749012/ Lilly to buy pain drug developer SiteOne, challenging Vertex | BioPharma Dive The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8. to buy biopharma dive lilly pain drug https://www.biopharmadive.com/news/merck-keytruda-prostate-biliary-trial-success-setback/641189/ Merck reports one success, one setback from late-stage Keytruda trials | BioPharma Dive The top-selling immunotherapy bested chemo in treating bile duct cancer, but fell short in a study testing it with other drugs for metastatic prostate tumors. late stage biopharma dive merck reports one https://www.biopharmadive.com/news/viking-obesity-drug-maintenance-study-results/831004/ Viking shares surge on updated obesity drug data | BioPharma Dive Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that could strengthen Viking’s... obesity drug biopharma dive viking shares surge https://www.biopharmadive.com/news/moderna-mflusiva-mrna-flu-vaccine-fda-committee-vote/823275/ Moderna flu vaccine wins unanimous support from FDA panel | BioPharma Dive The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to review earlier this year. flu vaccine biopharma dive moderna wins unanimous https://www.biopharmadive.com/topic/clinical-trials/ Clinical Trial News | BioPharma Dive The latest clinical trial news for biotech and biopharmaceutical professionals clinical trial biopharma dive news https://www.biopharmadive.com/news/pfizer-duchenne-patient-death-gene-therapy-trial/715450/ Patient dies in Pfizer study of Duchenne gene therapy | BioPharma Dive Pfizer said the patient, a young boy who was treated earlier last year, died suddenly from cardiac arrest. The company is working with trial researchers to... gene therapy biopharma dive patient dies pfizer https://www.biopharmadive.com/news/moderna-canada-vaccine-factory-never-again/604729/ Eyeing future outbreaks, Moderna partners with Canadian government on vaccine plant | BioPharma Dive While Canada has already secured more COVID-19 vaccine doses than it needs, the factory to be built is geared toward combating future pandemics. canadian government biopharma dive eyeing future outbreaks https://www.biopharmadive.com/news/novartis-avidity-acquire-deal-rna-drugs-neuromuscular-disease/803817/ Novartis to acquire Avidity in $12B bet on RNA drugs for neuromuscular disease | BioPharma Dive The deal, which Novartis expects can “unlock multibillion-dollar opportunities” in the years ahead, hands the company a group of medicines for multiple forms... bet on neuromuscular disease biopharma dive novartis acquire https://www.biopharmadive.com/news/novartis-ifm-tre-acquires-immune-disease-drugs/710124/ IFM, an unorthodox biotech startup, scores third buyout with Novartis deal | BioPharma Dive With a decision by the Swiss pharma to acquire another one of its subsidiaries, IFM Therapeutics has now sold three spin-offs for a total of $700 million... biopharma dive ifm unorthodox biotech startup https://www.biopharmadive.com/news/biogen-tofersen-fda-confirmatory-trial-advisory-committee/645513/ FDA staff signal support for Biogen ALS drug, but highlight data hurdles | BioPharma Dive In documents released Monday, agency staff appeared inclined to approve Biogen’s tofersen, which failed in its main trial. Gathering confirmatory evidence of... support for biopharma dive fda staff signal https://www.biopharmadive.com/news/takeda-fda-sleep-drug-approval-orexin-orzeyful-narcolepsy/827190/?ref=techarcade.io Takeda approval ushers in new wave of sleep drugs | BioPharma Dive An FDA nod mostly clears the way for Orzeyful to enter, by Wall Street estimates, a multibillion-dollar market for drugs that boost “orexin” proteins. ushers in new wave sleep drugs biopharma dive takeda https://www.biopharmadive.com/news/fda-oks-spinal-cord-injury-stem-cell-trial-for-asterias/303331/ FDA OKs spinal cord injury stem cell trial for Asterias | BioPharma Dive The experimental treatment will be used on 13 participants in a safety study. spinal cord injury stem cell biopharma dive fda oks https://www.biopharmadive.com/news/advocates-slam-protracted-uk-negotiations-over-novartis-meningitis-b-vaccin/331135/ Advocates slam protracted UK negotiations over Novartis meningitis B vaccine | BioPharma Dive UK scientists recommended that all infants should be given the vaccine back in March. But negotiations with Novartis didn't start until August—and dozens of... meningitis b biopharma dive advocates slam protracted https://www.biopharmadive.com/spons/pharmas-real-world-data-dilemma-strategic-asset-or-wasted-resource/801982/ Pharma’s real-world data dilemma: Strategic asset or wasted resource? | BioPharma Dive To maximize RWD’s potential, pharma companies should begin with their business or clinical goals. real world data biopharma dive dilemma strategic asset https://www.biopharmadive.com/news/third-rock-ventures-secures-616m-in-new-biotech-fund/429391/ Third Rock Ventures secures $616M in new biotech fund | BioPharma Dive The Boston-based venture capital firm has had success with previous funds, backing biotechs such as Bluebird Bio, Editas Medicine and Afferent Pharma. third rock ventures biopharma dive secures new biotech https://www.biopharmadive.com/news/ucb-neurona-deal-acquisition-cell-therapy-epilepsy-biotech/817863/ UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B | BioPharma Dive The acquisition helps diversify UCB’s small molecule-centric arsenal of seizure treatments with a potentially one-off therapy in early testing for a... cell therapy to buy biopharma dive ucb betting https://www.sutrobio.com/tag/sutro-biopharma-announces-virtual-deep-dive-research-forum-next-gen-innovations-in-adcs/ Sutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs | Sutro... sutro biopharma deep dive research forum next gen announces https://www.biopharmadive.com/news/intra-cellular-bipolar-depression-drug-study/584926/ Intra-Cellular roars back on success in bipolar depression | BioPharma Dive Widening the number of eligible patients could make Intra-Cellular's schizophrenia pill a blockbuster, analysts forecast. roars back bipolar depression biopharma dive intra cellular https://www.biopharmadive.com/news/kaleo-auvi-q-payer-pbm/434765/ Payers balk at price of EpiPen rival | BioPharma Dive Kaleo Pharma set the list price of Auvi-Q at $4,500 — higher than Mylan's EpiPen — even as it promises low costs for patients. biopharma dive payers balk price epipen https://www.biopharmadive.com/news/biogen-mergers-acquisitions-alzheimers-immunology-rare-disease/553370/ Biogen points to M&A power as Wall Street presses for less risky programs | BioPharma Dive Executives suggested Biogen may find external opportunities in the areas of immunology and rare disease, but cautioned that the company was likely to continue... m a wall street biopharma dive biogen points https://www.finanznachrichten.de/nachrichten-medien/risknet-8.htm BioPharma Dive | Nachrichten Aktuelle BioPharma Dive News: Scribe's Benjamin Oakes on a rare IPO and bringing CRISPR to the masses biopharma dive nachrichten https://www.biopharmadive.com/news/lilly-cfo-smiley-resigns-ashkenazi/594784/ Lilly CFO steps down after investigation found 'inappropriate' behavior | BioPharma Dive Josh Smiley had engaged in "consensual though inappropriate" personal communications with certain employees, according to Lilly. He's being replaced by Anat... steps down inappropriate behavior biopharma dive lilly cfo https://www.biopharmadive.com/ Biotech and Pharma Industry News | BioPharma Dive BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development,... pharma industry biopharma dive biotech news https://www.biopharmadive.com/news/oncomed-hit-with-another-mid-stage-failure/440579/ OncoMed hit with another mid-stage failure | BioPharma Dive The company's shares plummeted further after another Phase 2 trial flopped. hit with biopharma dive oncomed another mid https://www.biopharmadive.com/news/bridge-bio-oncology-launch-kras-cancer-drug-theras/714885/ BridgeBio spinout launches with $200M for KRAS cancer drugs | BioPharma Dive The company, BridgeBio Oncology Therapeutics, has one drug in the clinic and hopes to soon advance two other candidates. cancer drugs biopharma dive bridgebio spinout launches https://www.biopharmadive.com/news/amgen-pfizer-biosimilar-growth-herceptin-avastin/571502/ Amgen, Pfizer biosimilar sales pressure top drugs | BioPharma Dive Competition is heating up for copycats to Roche's top-selling cancer drugs, as the U.S. biosimilar market shows some modest signs of shifting. biopharma dive amgen pfizer biosimilar sales https://www.biopharmadive.com/news/sanofi-multiple-sclerosis-btk-inhibitor-troubles/809443/ What Sanofi’s multiple sclerosis troubles could mean for the space | BioPharma Dive Regulatory and clinical roadblocks have set back its oral BTK inhibitor tolebrutinib, but the drug class still has many opportunities to make an impact. multiple sclerosis for the biopharma dive troubles could https://www.biopharmadive.com/news/biotech-reverse-mergers-public-markets-ipo/829197/ A booming business on Wall Street would love more biotechs to quietly die | BioPharma Dive booming business wall street love more biopharma dive would https://www.biopharmadive.com/news/tariffs-trump-impact-medical-devices-manufacturing/740040/ How Trump’s trade fight could impact the medical device industry | BioPharma Dive Relocating manufacturing would require substantial capital investment, but the timespan for the president’s new tariffs is unclear, supply chain experts said. the medical biopharma dive trade fight could https://www.biopharmadive.com/news/coronavirus-gilead-remdesivir-orphan-drug/574882/ In rare move, Gilead gives up 'orphan' status for experimental coronavirus drug | BioPharma Dive After sparking controversy, the biotech asked the FDA to rescind a designation designed to encourage research into therapies for rare diseases. gives up orphan status biopharma dive rare move https://www.biopharmadive.com/news/insulin-makers-targeted-in-pricing-inquiries/441879/ Insulin makers targeted in pricing inquiries | BioPharma Dive Eli Lilly disclosed it is under investigation by the attorneys general of Washington and New Mexico. Rival Novo Nordisk is under similar scrutiny. biopharma dive insulin makers targeted pricing https://www.biopharmadive.com/news/ohio-voters-knock-down-drug-pricing-initiative/510383/ Ohio voters knock down drug pricing initiative | BioPharma Dive About 80% of voters cast ballots against Issue 2, which would have prevented the state from buying prescription drugs at prices higher than what the Department... knock down drug pricing biopharma dive ohio voters https://www.biopharmadive.com/news/lipocines-testosterone-drug-rejected-again/523165/ Lipocine's testosterone drug rejected again | BioPharma Dive The biotech confirmed receipt of an FDA complete response letter, but insisted the issues thwarting approval are not insurmountable. biopharma dive testosterone drug rejected